GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects

Curr Atheroscler Rep. 2009 Mar;11(2):93-9. doi: 10.1007/s11883-009-0015-9.

Abstract

Cardiovascular disease is a leading cause of death in the United States and across the world, and better therapies are constantly being sought to improve patient outcomes. Recent studies have brought our attention to the mechanisms of glucagon-like peptide 1 (GLP-1). Not only does it demonstrate beneficial effects in regard to cardiovascular risk factors (i.e., diabetes, lipid management, and weight control), but it also has been shown in animal studies to have positive cardiac effects irrespective of its effects on glucose control and weight loss. This review discusses the biology of GLP-1 and its effects on cardiovascular risk factors, and it also elaborates on the positive direct cardiovascular outcomes of GLP-1 in animal studies.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Glucagon-Like Peptide 1 / agonists*
  • Glucagon-Like Peptide 1 / pharmacology
  • Hypoglycemic Agents / therapeutic use*

Substances

  • Hypoglycemic Agents
  • Glucagon-Like Peptide 1